Head and Neck Cancer Research - Penn State Cancer Institute
Head and Neck Cancer Research
Research into head and neck cancer at Penn State Cancer Institute is conducted by the dedicated head and neck cancer team. See current clinical trials and members of that team here.
Clinical Trials
Effect of oral black raspberry administration on oral cell DNA adducts in smokers
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
The COVID-19 and Cancer Consortium (CCC19) Registry
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
HPV ECHO: Increasing the adoption of evidence-based communication strategies for HPV vaccination in rural primary care practices.
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ACR 3518: Phase I Safety Assessment of Hypofractionated Postoperative Radiotherapy (H-PORT) for Intermediate-Risk Head and Neck Cancer
Head and Neck Cells: Tissue Repository
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Melissa | Boltz | DO | ||
 |
David | Goldenberg | MD | ||
 |
Neerav | Goyal | MD, MPH | ||
 |
Diane | Hershock | MD, PhD | ||
 |
Jessyka | Lighthall | MD | ||
 |
Mitchell | Machtay | MD | ||
 |
Brian | Saunders | MD |
Research into head and neck cancer at Penn State Cancer Institute is conducted by the dedicated head and neck cancer team. See current clinical trials and members of that team here.
Effect of oral black raspberry administration on oral cell DNA adducts in smokers
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
The COVID-19 and Cancer Consortium (CCC19) Registry
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
HPV ECHO: Increasing the adoption of evidence-based communication strategies for HPV vaccination in rural primary care practices.
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ACR 3518: Phase I Safety Assessment of Hypofractionated Postoperative Radiotherapy (H-PORT) for Intermediate-Risk Head and Neck Cancer
Head and Neck Cells: Tissue Repository
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Melissa | Boltz | DO | ||
|
David | Goldenberg | MD | ||
|
Neerav | Goyal | MD, MPH | ||
|
Diane | Hershock | MD, PhD | ||
|
Jessyka | Lighthall | MD | ||
|
Mitchell | Machtay | MD | ||
|
Brian | Saunders | MD |